课题基金 / 基金详情

Linking defects in the uptake transporter OCT1 with cancer patients resistance towards anthracyclines

Linking defects in the uptake transporter OCT1 with cancer patients resistance towards anthracyclines
将摄取转运蛋白 OCT1 的缺陷与癌症患者对蒽环类药物的耐药性联系起来
批准号：
357190
负责人：
Ramotar Dindial
金额：
$72.45万
依托单位：
Centre de recherche de l'Hôpital Maisonneuve-Rosemont (Montral)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-10-01 至 2021-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=357190&lang=en
关键词：
Anticancer Agents, Anthracyclines, Cisplatin Crispr Library Dna Sequencing Drug Uptake Studies Epifluorescent Microscopy Gene Expression Microarray Analysis High Throughput Screens For Small Molecules Organic Cation Transporters Patients Samples,

项目摘要

项目成果

Ramotar Dindial的其他基金

相似基金

相关文献

中文摘要
翻译
我们最近发现，表面通透酶OCT 1执行允许抗癌药物进入细胞的功能。这些药物，如蒽环类，用于治疗各种癌症。我们发现，OCT 1水平是关键的积累，
英文摘要
We have recently discovered that the surface permease OCT1 performs a function to allow anticancer drugs to enter into cells. These drugs, such as anthracyclines, are used for treating various cancers. We show that OCT1 level is critical for the accumulat
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of human glyceraldehyde-3-phosphate dehydrogenase in maintaining the redox state of the DNA repair enzyme APE1
The role of human glyceraldehyde-3-phosphate dehydrogenase in reactivating oxidized forms of the DNA repair enzyme APE1
海外基金